Ken Griffin Ocular Therapeutix, Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$6.45 - $9.23 $167,700 - $239,980	26,000 Added 198.47%	39,100 $340,000
Q2 2024 Aug 14, 2024	SELL	$4.2 - $8.69 $87,360 - $180,752	-20,800 Reduced 61.36%	13,100 $89,000
Q1 2024 May 15, 2024	SELL	$3.85 - $10.93 $35,420 - $100,556	-9,200 Reduced 21.35%	33,900 $308,000
Q4 2023 Feb 14, 2024	SELL	$2.08 - $4.52 $1,664 - $3,615	-800 Reduced 1.82%	43,100 $192,000
Q3 2023 Nov 14, 2023	SELL	$3.14 - $5.04 $143,812 - $230,832	-45,800 Reduced 51.06%	43,900 $137,000
Q2 2023 Aug 14, 2023	SELL	$4.6 - $7.64 $1.1 Million - $1.83 Million	-240,000 Reduced 72.79%	89,700 $462,000
Q1 2023 May 15, 2023	BUY	$2.79 - $6.27 $718,704 - $1.62 Million	257,600 Added 357.28%	329,700 $1.74 Million
Q4 2022 Feb 14, 2023	BUY	$2.61 - $4.41 $7,308 - $12,348	2,800 Added 4.04%	72,100 $202,000
Q3 2022 Nov 14, 2022	BUY	$4.09 - $6.5 $230,676 - $366,600	56,400 Added 437.21%	69,300 $288,000

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $764M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.